Aptiv Solutions Reaches First Milestone in Delivering New Platform for Model-Based Dose-Finding Trials (ADDPLAN® DF)

Published: Feb 07, 2013

RESTON, Va.--(BUSINESS WIRE)--Aptiv Solutions, a biopharmaceutical and medical device development services company, and the leader in adaptive clinical trial design, simulation and execution, announces the completion of a key milestone in the development of a new platform for phase Ib and II adaptive design clinical trials. Both regulatory agencies and the pharmaceutical industry agree that poor understanding of dose response is a major cause of late phase product attrition, and recognize that they need to improve critical decision-making in early stage clinical development so that appropriate doses are progressed to pivotal studies.

Back to news